● Recruiting

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

Condition: Sarcoma · Cervical Cancer · Colon Cancer · Sponsor: GONGCHU Biotechnology Co., Ltd

PhasePhase 1

Planned participants21

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

The present trial is an open, single-arm phase I clinical study aimed at assessing the safety, tolerability, viral distribution and shedding patterns, pharmacodynamics, immunogenicity, and antitumor efficacy of GC001 oncolytic virus injection in patients with advanced solid tumors following a single administration.

This description comes directly from the study's public registry record.

Talk to the study team

Mo guoyu · 13710803863 · morlon_pla@126.com

luo suxia, Professor

Always discuss trial participation with your own doctor first.

Locations (1)

Henan Cancer Hospital

Zhengzhou, Henan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06508307